Mode
Text Size
Log in / Sign up
N/A N=19 Treatment

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

Functional Mitral Regurgitation

Enrolled (actual)
19
Serious AEs
63.2%
Results posted
Mar 2023
Primary outcome: Primary: The Primary Endpoint is Technical Success — 17 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA) (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Primary completion
Feb 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
The Primary Endpoint is Technical Success
17
SECONDARY
The Secondary Endpoint is Procedural Success
16

Summary

This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup). This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string. The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.

Eligibility Criteria

  • INCLUSION CRITERIA:
  • Adults age >=21 years
  • Symptomatic functional mitral valve regurgitation
  • Mild or greater mitral valve regurgitation, LVEF =0.20 assessed by echocardiography, CT, or CMR
  • Suitable coronary venous anatomy for Transcatheter Mitral Cerclage Annuloplasty based on pre-procedural cardiac CT or coronary venogram
  • Concordance of the Study Eligibility Committee
  • If present, a MitraClip was implanted at least 30 days previously

EXCLUSION CRITERIA

  • Subjects unable to consent to participate
  • Subjects unwilling to participate or unwilling to return for study follow-up activities.
  • Prior cardiac implanted electronic devices (CIED) likely to be entrapped by cerclage.

-- Candidates with coronary sinus or left ventricular pacing or defibrillation leads that are not likely to be entrapped by cerclage, evident on baseline CT or angiogram, are eligible to participate.

  • TAVR within 6 weeks
  • Intended concurrent structural heart procedure, such as aortic or tricuspid valve intervention
  • Aortic stenosis more than mild in severity
  • Single-leaflet MitraClip detachment, if present
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03929913). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search